Denosumab
- Generic Name
- Denosumab
- Brand Names
- Prolia, Xgeva, Wyost, Jubbonti
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 615258-40-7
- Unique Ingredient Identifier
- 4EQZ6YO2HI
- Background
Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption markers in patients with a variety of metastatic tumors and is being investigated in multiple clinical trials for the prevention and treatment of bone metastases. Chemically, it consists of 2 heavy and...
- Indication
Prolia is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture. It reduces the incidence of vertebral, nonvertebral, and hip fractures. Prolia is also indicated as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer. It can also be use...
- Associated Conditions
- Bone Fractures, Bone Giant Cell Tumor, Bone Loss, Bone pain, Spinal Cord Compression, Bone destruction, High risk of fracture Osteoporosis, Refractory Hypercalcemia of malignancy
- Associated Therapies
- -
Denosumab vs Placebo in Patients With Thalassemia Major and Osteoporosis
- First Posted Date
- 2015-09-24
- Last Posted Date
- 2019-08-26
- Lead Sponsor
- Ersi Voskaridou
- Target Recruit Count
- 63
- Registration Number
- NCT02559648
- Locations
- 🇬🇷
General Hospital of Athens "Laikon", Athens, Attica, Greece
Osteoclast Inhibition and Bone Formation
- First Posted Date
- 2015-09-18
- Last Posted Date
- 2018-01-05
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 81
- Registration Number
- NCT02554695
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Denosumab Safety Assessment in Multiple Observational Databases
- First Posted Date
- 2015-08-11
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Amgen
- Target Recruit Count
- 517991
- Registration Number
- NCT02520362
Zoledronic Acid to Maintain Bone Mass After Denosumab Discontinuation
- Conditions
- Interventions
- First Posted Date
- 2015-07-16
- Last Posted Date
- 2019-03-11
- Lead Sponsor
- 424 General Military Hospital
- Target Recruit Count
- 57
- Registration Number
- NCT02499237
- Locations
- 🇬🇷
251 Airforce & VA General Hospital, Athens, Greece
🇬🇷424 General Military Hospital, Thessaloniki, Greece
Effects of Denosumab Therapy for Japanese
- Conditions
- First Posted Date
- 2015-07-08
- Last Posted Date
- 2016-11-25
- Lead Sponsor
- Tomidahama Hospital
- Target Recruit Count
- 500
- Registration Number
- NCT02491515
- Locations
- 🇯🇵
Tomidahama Hospital, Yokkaichi, Mie, Japan
Longjohn Amgen Study - Effect of Denosumab...
- First Posted Date
- 2015-05-14
- Last Posted Date
- 2020-11-10
- Lead Sponsor
- University of Southern California
- Registration Number
- NCT02444585
- Locations
- 🇺🇸
Keck Medicine of USC, Los Angeles, California, United States
Longitudinal Effects of Denosumab on Trabecular Bone Score and Femur Strength Index
- Conditions
- First Posted Date
- 2015-05-06
- Last Posted Date
- 2018-10-29
- Lead Sponsor
- HealthEast Care System
- Target Recruit Count
- 86
- Registration Number
- NCT02435147
- Locations
- 🇺🇸
HealthEast Care System, Saint Paul, Minnesota, United States
TNFSF11 Inhibition and Fertility: a Prospective Study
- First Posted Date
- 2015-04-21
- Last Posted Date
- 2019-03-27
- Lead Sponsor
- Martin Blomberg Jensen
- Target Recruit Count
- 12
- Registration Number
- NCT02422108
- Locations
- 🇩🇰
Rigshospitalet, Copenhagen, Denmark
Denosumab for Glucocorticoid-treated Children With Rheumatic Disorders
- First Posted Date
- 2015-04-16
- Last Posted Date
- 2019-12-06
- Lead Sponsor
- Indiana University
- Registration Number
- NCT02418273
- Locations
- 🇺🇸
Indiana University School of Medicine, Indianapolis, Indiana, United States
Trial of Ra-223 Dichloride in Combination With Hormonal Therapy and Denosumab in the Treatment of Patients With Hormone-Positive Bone-Dominant Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-02-19
- Last Posted Date
- 2021-10-07
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 45
- Registration Number
- NCT02366130
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.